Načítá se...
SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants
SB 9200 is a novel, first-in-class oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus and influenza an...
Uloženo v:
| Vydáno v: | J Med Virol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5513743/ https://ncbi.nlm.nih.gov/pubmed/28303593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.24809 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|